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ABSTRACT
Recent studies suggest that health inequalities across socio-economic groups in the US are large and
have been growing. We hypothesize that, as in other, non-health contexts, this pattern occurs
because more educated people are better able than to take advantage of technological advances in
medicine than are the less educated. We test this hypothesis by relating education gradients in
mortality with measures medical innovation. We focus on overall mortality and cancer mortality,
examining both the incidence of cancer and survival conditional on disease incidence. We find
evidence supporting the hypothesis that education gradients are steeper for diseases with more
innovation.
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Socioeconomic disparities in health have increased over the past century in the 
U.S., the U.K., and continental Europe (Feldman et al., 1989, Pappas et al., 1993, 
Prston and Elo, 1994, Black Report, 1980, Kunst et al., 2001, Shkolnikov et al., 
1998).  In the U.S., between 1960 and 1986, the age-adjusted mortality rate for white 
men who had attended college declined from 5.7 to 2.8 per 1000, while the rate 
declined only from 9 to 7.6 for those who had not graduated high school (Pappas et 
al., 1993).  Moreover, the principal causes of death and disability generating 
socioeconomic differentials today are quite different from those a century ago 
(McKeown, 1976; Cutler and Meara, 2002).  Over this period, housing, nutrition, and 
sanitation have improved; the infectious diseases that were the prime causes of death 
before World War I account for little mortality today; and access to effective medical 
care for those diseases that remain has become more widespread.  Today, gradients are 
largest for chronic diseases.   
Many factors can generate socioeconomic differences in health status at a point 
in time.  What is more difficult to explain is that these differentials have increased 
and have shifted among diseases during the past century (Carroll, Davey, Smith, and 
Bennett, 1996).  To our knowledge there is no existing research that has 
systematically investigated the question of why gradients move among diseases and 
widen over time. 
In this paper we propose and test one explanation for this pattern: the gradient 
moves among diseases because more educated people are able to exploit technological 
advances in medicine more rapidly.  For this reason, the gradient increases where and 
when technological change occurs. The most educated make the best initial use of new 
information about different aspects of health.  Over time, this information diffuses 
along the education gradient.  Thus, all else equal, if technological change ceased, we 
would expect the gradient to flatten as well.   
Our hypothesis is an extension to health of Nelson and Phelps’ (1966) theory 
that “the return to education is greater the faster the theoretical level of technology 
has been advancing (p. 72).”  A substantial literature examines this pattern in the 
labor market (see, for example, Bartel and Sicherman, 1999; Allen, 2001) and in the 
agricultural sector (Wozniak, 1984). Our hypothesis is also closely related to the 
sociological conjecture that socioeconomic status is a “fundamental social cause” of 
gradients in health (Link and Phelan 1995, Link, et al., 1998).  A fundamental cause is   2
one that involves access to resources that can be used to avoid or minimize risks, 
influences multiple risk factors, and affects multiple disease outcomes. In this view, 
higher socioeconomic status enables people to better exploit new information and 
resources. 
A recurring difficulty in the literature associating gradients in wages to 
technological progress is the difficulty of measuring progress (Griliches, 1994).  This 
problem also arises in our context and we follow the labor literature in addressing it 
by considering several different measures of technological progress.  We examine the 
effects of these measures in two different datasets that have distinctive strengths and 
weaknesses for this analysis.  Although our data are limited in several dimensions, we 
find evidence that is generally (though not uniformly) supportive of our hypothesis: 
gradients appear to be largest for diseases where there has been more progress.  
This paper is organized as follows. We first present a simple formalization of 
our proposed explanation of the relationship between education, health, and the rate of 
innovation (Section II).  We then present a case study of the HIV epidemic to 
illustrate how such gradients may evolve.   
In Section III, we describe our measures of progress and our empirical 
approach. In section IV we look at gradients in 5-year mortality across all diseases 
using data from the National Health Interview Survey (NHIS).  We then relate our 
estimated education gradients to disease categories with divergent rates of progress.   
In Section IV, we focus on gradients in cancer incidence and 5-year survival 
(conditional on stage of diagnosis) using data from the Surveillance, Epidemiology 
and End Results (SEER) database. Among diseases, cancer is second only to 
cardiovascular diseases as a contributor to educational gradients in mortality. Cancer 
provides a good area to study because improvements (albeit small) have occurred in 
the incidence, diagnosis, and treatment of several cancers, and these improvements 
vary substantially among cancer subtypes.
1 Additionally, the SEER data links cancer 
diagnosis to cancer outcomes in a consistent way across subtypes, whereas for other 
diseases, surveillance data on risk factors cannot be as readily linked to outcomes.
2   
                                                 
1 For example, there have been substantial improvements in survival after diagnosis of early stage colon cancer 
(DHHS, 2001). Progress has been made in diagnosing breast and prostate cancer.   
2 For example, people with high cholesterol or high blood pressure are at risk of mortality from multiple 
diseases, making it difficult to link mortality outcomes for each of these diseases with progress.   3
In Section V, we examine how changes in progress affect changes in the 
education gradient.  In Section VI, we evaluate different causal explanations of our 
results.  In Section VII, we relate gradients to technological progress prospectively.  
Section VIII concludes.  
 
II. – Relating Outcomes to Progress 
Many recent studies of health status differentials focus on gradients associated 
with education. These studies generally find that education is closely correlated with 
health status (even controlling for income), and suggest that the relationship is 
causal.
3 Several explanations have been proposed. Grossman (1972) suggested that 
education leads to better health by improving the technology for health production.  
This might include having access to more information about health risks, making 
better use of that information or more effectively searching for high quality health 
providers (Rosenzweig, 1995).   
Education may also have indirect effects on health by increasing income and 
improving access to the resources needed to improve health. The extent to which 
education affects health may also depend on the available health care technology, 
because better-educated people might be better able to use certain health care 
technologies (Goldman and Lackdawalla, 2002).  Rather than understanding the 
specific mechanism than generate the education gradient for  particular disease at a 
given point in time, this paper’s objective is to understand what makes education 
gradients increase over time or shift from one disease to another.  To do this, we focus 
on the role of education in the diffusion of technological progress. 
A formalization of the relationship between health, education and the rate of 
innovation 
  The following formalization closely follows Nelson and Phelps (1966). This 
model is only illustrative.  It captures the basic features of our hypothesis in a simple 
fashion and provides guidelines for our empirical approach.  
  Suppose that the health H of an individual can be modeled as a function of the 
level of technology A that the individual has access to, and other inputs C: 
                                                 
3 For example see Lleras-Muney (2002) shows that increases in education induced by compulsory schooling 
laws lead causally to improvements in health status.    4
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T(t) is the level of technology if technology is instantaneously diffused and λ is the 
exogenous rate of technological progress. Suppose now that the level of technology 
available to any individual depends on how rapidly individuals adopt new 
technologies, and that the lag between innovation and adoption is a decreasing 
function of education, so that  
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where w’(e)<0. This key assumption captures the ideas that were presented in the 
introduction -- that is that the more educated “adopt” new technologies at a faster rate 
because of better access to information, better use of information, and better capacity 
to search for better providers and or treatments. This feature can be generated from 
maximization principles simply by assuming differential costs of technology adoption. 
Note that this model assumes that individuals have chosen education in previous 
periods and that technological changes are unanticipated. In this context, we can 
express the health of the individual as: 
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The derivative of the health production function with respect to education gives us 
what is known as “the education gradient” in health. It gives the marginal gain in 
health induced by an additional unit of schooling. In this model it can be expressed 
as: 
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Since w’(e) is negative, the model predicts that health is an increasing function 
of education and that the rate of return of education is larger the higher the rate of 
technological change. We can test this prediction in the data, first by estimating the 
disease-specific education gradient, and then by relating the size of the gradient to   5
measures of innovations that proxy for the parameter λ. Note that we think of 
technology here in very broad terms: it includes all innovations that affect the manner 
and the rate in which we can transform inputs into health. So in this view, new 
knowledge is considered innovation.  
This simple model predicts that in the absence of technological change (λ = 0), 
there should be no difference between the educated and the uneducated. We do not 
believe that technology adoption is the only reason why education and health might be 
related. For example, even in the absence of progress we can expect education 
gradients if the more educated are better at utilizing complex technologies (e.g. 
Rosenzweig, 1995 Goldman and Smith, 2001). A more elaborate model could 
incorporate these other mechanisms. As the literature review in the introduction 
showed, there is a substantial amount of work that has investigated these. We will 
therefore focus only on whether higher rates of technological progress are associated 
with larger gradients in our empirical work.
4 
 
A Case Study 
HIV disease provides an interesting case study of the relationship between 
education gradients and medical progress because the disease is new.  At the 
beginning of the HIV epidemic, in the early 1980s, before information about 
transmission or treatment was available, cases were concentrated among gay men, a 
group with substantially higher than average educational attainment: 67% have at least 
a college degree (Bozzette, 1998).   
Since the early 1980s, however, there have been markedly different trends in 
the HIV/AIDS epidemic for groups with different levels of education.  Behavioral 
changes among gay men began immediately after the method of transmission of the 
human immunodeficiency virus was identified in 1982.  In the largest study of 
transmissions in that period, new infections in this group fell from 20.8% of a 
susceptible cohort in 1982 to 2.1% of that cohort in 1983 (Centers for Disease 
Control, 1987).  By the late 1980s, new cases among gay men were well below 
                                                 
4 Note that there is no sense in which there exist general equilibrium effects in the health model: if everyone 
obtains more schooling everyone’s health improves.  While the income returns to education are determined by 
the labor market, the returns to education in health are only determined by the individual health production 
function. In this respect our theory differs from the “fundamental causes” theory in that it is not a zero sum 
game.   6
projected rates, while rates among IV drug users were at or above projected levels, 
suggesting that there had been little behavioral change in this group (Bloom and 
Glied, 1992). As early as 1983, new AIDS cases began to be concentrated in low-
income areas (Fordyce, 1998).  
The effects of new information on the gradient in HIV incidence were later 
magnified by the effects of new treatment technologies on HIV mortality.  We use 
data from the Centers for Disease Control WONDER system to map annual death rates 
among the population living with AIDS by exposure category (Figure 1). There were 
two major treatment advances in HIV care over this period. After a short period of 
clinical trials, the FDA approved the first effective AIDS drug, AZT, in 1987 (Brown, 
1987). A second, more effective, group of drugs, the highly active antiretroviral 
therapies (HAART) based on protease inhibitors, was introduced beginning in the late 
1990s.  The FDA approved the first HAART-related protease inhibitor, invirase, in 
December 1995 and the development of combination therapies that made use of these 
drugs followed over the subsequent 18 months (McGinley and Womack, 1995; 
Goldman and Lakdawalla, 2001).  As Figure 1 shows, the introduction of AZT and of 
HAART drugs was associated with a divergence in the death rate between gay men and 
other transmission groups.
5 This pattern suggests that the more educated group was 
quicker in taking advantage of the new treatment technology.   
Case studies of specific populations support this finding (see Appendix Table 
1).  Crystal, Sambamoorthi, and Merzel report that there were significant 
socioeconomic differences (measured by race and exposure group) in receipt of AZT 
in a cohort studied in 1987-1988, but that these differences had largely disappeared by 
1989-1990.  Two studies examine changing socioeconomic status disparities in 
HAART between 1996 and 1998 (Cunningham et al, 2001; Sambamoorthi et al, 2001).  
Cunningham et al. find that the gap between the percentage of college educated HIV-
infected people who had ever used HAART compared to the percentage among those 
with less than a high school degree shrank form 27 points in 1996 (49:22) to 14 points 
in 1998 (79:65).  Sambamoorthi et al, 2001 find a similar pattern in receipt of HAART 
over time by race and exposure group. 
                                                 
5 Note that these death rates are conditional on incidence of AIDS.  Our data do not capture the extent to which 
people with  HIV began taking these drugs before developing AIDS symptoms and never progressed to AIDS.     7
Today, lower educational attainment is highly correlated with mortality among 
AIDS patients (Schechter, 1994).  More highly educated patients are more likely to 
adhere to therapy (Goldman and Smith, 2002), have greater access to antiretroviral 
therapy and protease inhibitors (Sorvillo, 1999), are more likely to participate in 
clinical trials (Seltzer, 1989), and have far more knowledge about AIDS (Sorenson, 
1999).  The HIV case study provides an interesting example of how education may 
interact with new treatment technologies.  Several other case studies similarly 
document more rapid diffusion of new health innovations among more highly educated 
people relative to less educated people (see, for example, Link et al.  (1998)). In the 
next sections, we attempt to find more systematic evidence for this pattern. 
 
III. –Progress measures and empirical approach 
Measures of progress 
There is no consensus about how to measure either progress or the relative 
importance of progress (Allen, 2001; Bartel and Sicherman, 1999).  Instead, we 
compute multiple measures of innovation for each of the 55 diseases in the NHIS-
MCD and the 81 cancer sites in the SEER data. Table 1 describes these measures.  Not 
all progress measures are available in both datasets. 
Measurement of progress by disease is particularly problematic because 
progress in the prevention or treatment of one disease can leave a larger population 
susceptible to another disease.  Thus, the most straightforward measures of 
technological progress are those that describe innovation in survival conditional on 
diagnosis of a disease.
6 
1. Number of drugs 
The SEER data contain information on survival conditional on diagnosis.  We 
can link these data to information on the number of drugs approved by the FDA to 
treat a particular cancer (SEER), a direct measure of the rate of pharmaceutical 
innovation for each particular cancer site.
7  We cannot assign drugs to disease 
                                                 
6 Note that progress in the treatment or prevention of other diseases may still affect outcomes conditional on 
diagnosis if the newly susceptible population is different (for example, more or less fragile) from the original 
population. 
7 As in Lleras-Muney and Lichtenberg (2002) or Lichtenberg (2002), we use the number of new active 
ingredients approved by the FDA rather than the number of new drugs, which we consider a better measure of 
innovation in drug treatments (the FDA also approves generic equivalents and new dosages of the same drug   8
categories in the NHIS because the match between drugs and causes of death is highly 
imperfect, since drugs are used for conditions that can lead to death from multiple 
causes.  For example, drugs to control diabetes can reduce death rates from diabetes, 
heart disease, stroke, kidney failure, and other conditions.  
2. Change in 5-year survival rates 
Using the SEER data, we compute the change in the 5-year survival rate 
conditional on diagnosis.  Like the drug measure, this measure is related to innovation 
that affects survival conditional on diagnosis. Unlike drugs, which only capture a 
specific type of innovation, this measure is more comprehensive: progress in surgical 
procedures, radiation and other aspects will be reflected in the survival rate. However 
note that this measure is also affected by innovations in diagnostic technology that 
lead to cancers being diagnosed earlier.
8  Over this period, survival conditional on 
diagnosis has increased. 
3. Change in age-adjusted mortality 
A broader measure of progress, which can be confounded by changes in disease 
incidence, is the change in the age-adjusted mortality rate. The National Cancer 
Institute provides a measure of the trend in age-adjusted mortality from each type of 
cancer: the estimated annual percent change (EAPC), which is the coefficient from a 
log-linear regression of mortality rates on calendar year.  The EAPC is positive if age-
adjusted mortality increased and negative if age-adjusted mortality decreased; 
therefore a negative value for EAPC constitutes progress.  Across all 81-cancer sites 
there has been progress in cancer mortality over this period.   
For the NHIS data we calculate the same measure (EAPC) of age-adjusted 
mortality using data from the compressed mortality files provided by the CDC. The 
compressed mortality files provide us with age-adjusted mortality rates for whites for 
each year from 1986 to 1995 that we use to calculate the EAPC using the same method 
that the National Cancer Institute uses.  
4. Changes in age-adjusted incidence 
                                                                                                                                                             
for example). For each cancer site we compute the number of drugs that exist in the market as of 1999.  These 
data were constructed using several sources: First Data Bank provided a list of the drugs that are used to treat 
cancers, and the date of FDA approval of the active ingredient in each drug was kindly provided by Frank 
Lichtenberg. 
8 We examine this directly by evaluating changes in the gradient in stage of diagnosis, discussed in footnote xx 
below, and by controlling for stage of diagnosis in the regression analyses.   9
A final measure of technological change is innovation in disease prevention.  
New knowledge associated with disease prevention should allow people to avoid 
getting a disease in the first place.  Unfortunately, we do not have any direct measures 
of information about disease risk factors.   
The efficiency with which epidemiologists are able to identify risk factors for 
disease increases as the proportion of all susceptible people who develop the disease 
approaches 0.5 (Rothman and Greenland, 1998).  In our context, the prevalence of 
every disease or disease subtype in the population is well below 0.5.  This suggests 
that the amount of available information about risk factors for a disease or disease 
subtype will be increasing in the incidence of that disease.
9  We conjecture that as 
disease incidence increases, information (and gradients) also increase.  This pattern 
should hold even if increases in disease incidence are simply a consequence of 
improvements in the prevention and treatment of other diseases.  We examine this 
interpretation of changes in incidence in Section VII below. 
The National Cancer Institute provides a measure of the trend in age-adjusted 
incidence: the estimated annual percentage change in age-adjusted incidence (EAPCI). 
In light of our argument above, positive EAPCI values constitute proxies for progress 
in the identification of disease risk factors. Overall, incidence rates for most cancer 
subtypes have increased.  Note that there are multiple reasons why incidence could 
increase including advances in diagnostic technology, increases in environmental risk 
or in progress in the prevention and treatment of other diseases (who leave more 
people alive and susceptible to cancer). Our conjecture that information about risk 
factors increases with increasing prevalence should hold regardless of the causes for 
increasing incidence.
10  Innovation measures by disease are listed in appendices A and 
B. 
While these measures are related to one another, the correlation among them is 
not very high, suggesting that they all describe distinct components of progress (Table 
2).  Changes in incidence and mortality are positively and highly correlated. Increases 
in survival and in mortality are negatively correlated, but survival and incidence are 
not highly correlated. Both incidence and mortality are positively correlated with new 
                                                 
9 In a preliminary search of Medline, we found that publications on the etiology of diseases are increasing in 
disease prevalence. 
10 Note that as information about risk factors diffuses incidences will fall, and so we would expect incidence 
to diminish   10
drugs, which may indicate that pharmaceutical manufacturers target diseases with 
rising incidence (as we discuss below).  Drugs are positively correlated with changes 
in survival.   
Empirical implementation Across Diseases and Disease Subtypes 
  Our hypothesis suggests that gradients in education should be greatest 
where medical progress has been greatest.  Our empirical strategy to evaluate this 
hypothesis consists in estimating education gradients (by disease or disease subtype) 
and relating these gradients to measures of medical progress.  Although there exist 
different measures of the gradient, in this study we always define gradients as the 
difference (rather than the ratio) in health outcomes between educated and uneducated 
individuals.  We consider three empirical specifications.   
In the most flexible, specification, which we employ in both the NHIS and 
SEER data, we estimate separate regressions for each disease (NHIS) or cancer site 
(SEER), including a full set of controls, 
(1)  n j e X education died P ij ij ij j ij ... 1 , ) 1 ( 1 0 = + + + = = γ β β . 
where i indexes individuals, and j indexes the n different diseases. We use the 
coefficient on education from each regression as the dependent variable in the second 
stage regression that contains as many observations as disease gradients (n), 
(2)  n j progress j j j ... 1 , 1 0 = + + = ε δ δ β  
  According to our hypothesis, we expect δ 1 to be negative: larger progress translates 
into more negative gradients. In this fully flexible form, none of the variables are 
constrained to be the same across sites.   
Unfortunately, because of the very large number of dummy variables in our 
SEER specification, there is little statistical power available to identify results using 
this specification in these data so for these data, we begin with two less flexible 
specifications.
11  In the least flexible specification, we estimate a linear probability 
model of the probability of dying within 5 years after diagnosis (conditional on stage 
at diagnosis), where education is interacted with progress:  
                                                 
11 In principle, the dummy variables alone fully identify 73,782 observations, and for many cancer sites we 
have far fewer observations available (see Appendix 1).   11
(3)  e X progress education education died P + + + + = = γ β β β * ) 1 ( 2 1 0 . 
Our model suggests β2 should be negative. Note that in this specification we constrain 
the coefficients on all variables to be the same across all cancer sites, except that we 
allow education to vary with our measure of medical progress. 
  In a second, preferred specification, we free up the functional form by 
separating the two stages. Initially, we run a single individual level regression, 
including a full set of controls and interacting education with cancer site dummies and 
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where i indexes individuals, and j indexes the 81 different cancers. As with the fully 
flexible form, the resulting 81 coefficients (labeled βj) from the interaction terms 
(education*cancer site) become the dependent variable in a second stage regression 
where medical progress related to that cancer site is the independent variable:   
(5)  81 ... 1 , 1 0 = + + = j progress j j j ε δ δ β  
In this specification, the effects of education and stage are allowed to vary by cancer 
site, but all other variables are constrained to have the same effect across sites.  As in 
the fully flexible specification, measures of progress are not included when estimating 
education gradients, eliminating the possible endogeneity of the progress measures 
with respect to the probability of dying. 
 
IV- Gradients by Disease – Results from the NHIS  
Data 
We first measure education gradients in mortality using the NHIS-MCD files. 
The NHIS is an annual cross sectional survey of the U.S. population. All respondents 
18 years of age or older in the 1986-1994 surveys were subsequently matched to the 
Mortality Cause of Death (MCD) files from 1986 to 1995. Following the 
epidemiological literature, we focus on five-year mortality and, to avoid censoring, 
use only observations from the 1986-1990 NHIS interviews. The data contain several 
socio-economic variables including years of education and family income, and the   12
mortality data contain information on all causes of death. For purposes of comparison 
with the cancer data described below, we restrict the NHIS sample to whites ages 40 
and above. In all, our sample from the NHIS-MCD files contains 164,373 
observations. Summary statistics for the NHIS-MCD data are reported in Table 3.   
The Effect of Education on Mortality 
We first examine the overall effect of education on the probability of surviving 
5 years.  We estimate the model in (1) above where the X includes Hispanic status, 
gender, marital status, interview year and single years-of-age dummies.
12  T a b l e  4  
documents the gradient in education for all-cause mortality. The effect of education is 
negative and significant, slightly larger for males than for females but this difference 
is not statistically significant. At the mean, these coefficients imply that one more 
year of education reduces 5-year mortality by about 5%. Table 5 shows the results by 
disease category for broad categories. We find a negative effect of education on 
mortality from cancer, respiratory system diseases, cardiovascular diseases, digestive 
system diseases and other diseases. The effect of education on mortality from diabetes 
or infectious diseases is negative but not statistically significant.   
The Effect of Progress on the Gradient 
  We next relate the education gradients by disease with progress in mortality for 
that disease. Figure 2 shows the relationship for broad disease categories. The figure 
shows (excluding digestive and genitourinary diseases), consistent with our 
hypothesis, that the gradient is largest for diseases where mortality has decreased 
most.  
We next examine the relationship using 55 detailed categories of death.
13  For 
each cause of death we estimate the effect of education on the probability of dying in 
the next five years as in tables 4 and 5. We then match coefficients from these 
regressions to changes in disease-specific mortality. Table 6 presents results from 
regressions that are weighted by the number of deaths from that disease in our sample 
(column 1) and by the inverse of the variance of the first stage coefficient (column 2).   
                                                 
12 Cox proportional hazard models yielded similar results but given that the data are large and that we include 
many variables, these estimations take a very long times to converge. We therefore present linear probability 
models instead. 
13 The NHIS-MCD recodes ICD9 causes of death into 72 categories. We use this classifications We excluded 
deaths from external causes, deaths from birth complications, deaths from ill-defined causes, and causes of 
death for which we did not observe any deaths. See appendix B for a detailed list of the causes of death we 
use.   13
When weighting by the number of deaths, we find that the gradient in education 
is larger and statistically significant for diseases where there has been more progress. 
Medical progress, measured as changes in mortality, explains about 13.6% of the 
gradient in education (evaluated at the mean for progress, i.e., 
0.0000612*1.067/0.0048).  When weighting by the standard error of the coefficient, 
however, the result is negative but much smaller and not statistically significant.   
In order to investigate why the different weights strongly affect the results, we 
plotted education gradients and their standard errors against the number of deaths in 
that disease (Figure 3). Figure 3 shows that both gradients and standard errors are 
larger for more common diseases. That the standard errors increases with the number 
of deaths is not surprising: the variance of a binary random variable is (1-p)p, and 
since p (the probability of dying, i.e. the number of deaths divided by population) is 
always less than 0.5, the variance increases with the number of deaths. But note that 
gradients increase with the number of deaths. Therefore weighting by the standard 
error leads us to place the most weight on rare causes of death. We conclude that the 
regressions that are weighted with the number of deaths are more accurate.  
Note that this exercise has uncovered an interesting pattern that is consistent 
with our hypothesis about progress in incidence.  Education gradients appear to 
increase with disease incidence.  We discuss this pattern more extensively below. 
 
V.  Gradients by Disease Subtype – Results from the SEER 
Data 
Our cancer data come from the SEER Cancer Incidence Public Use Database 
collected by the National Cancer Institute. The data contain information on every 
person diagnosed with cancer from 1973 to 1998 in 9 SEER registries. The SEER 
registries are composed of several counties located in San Francisco, Connecticut, 
Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.
14  Information on vital 
status was recorded for all individuals in the sample as of 1998. These data allow us 
to look at mortality rates conditional on cancer diagnosis. To avoid censoring in our 
analysis of 5-year mortality, we limit our sample to those diagnosed with cancer no 
                                                 
14 The Seer data include two more registries (San Jose and LA) but we exclude them since data are only 
available from 1992 to 1998 for these registries.   14
later than 1993.  The SEER data contain a large number of observations 
(N=2,556,432) so we can perform analyses of death rates within detailed disease 
category (sites).  
We focus on two outcome measures in the cancer data:  5-year mortality rates 
and cancer incidence rates.  We focus most of our attention on gradients in mortality 
rates (conditional on stage of diagnosis), because these gradients are relatively 
independent of trends in the incidence of other diseases. 
Summary statistics for the final SEER sample used in this paper are in Table 7.  
Average age at diagnosis for this sample is around 70. About 2/3 of the population 
died within 5 years of diagnosis. The most common cancers are cancers of the 
digestive system, of the respiratory system and of the genital system. Note that our 
sample is relatively old because we exclude people born after 1925.
15  
Education Measures 
Unfortunately, the SEER registry data do not include information on 
educational status.  Instead, we use two distinct proxies for educational status – 
compulsory schooling laws and average education level by cohort and registry.  
The SEER data contain information about state of birth, year of birth, gender 
and race. We can therefore match individuals to compulsory attendance and child 
labor laws in place in their state of birth when they were 14 years of age. Several 
papers have shown that these laws had an impact on educational attainment.
16 These 
laws, which implicitly specified the number of years that a child had to attend school, 
serve to identify the effect of education.
17 The implicit number of compulsory years 
ranges from 0 to 10 for the cohorts we study.  
By including laws in place of education in a model of mortality/health, we are 
estimating a reduced form equation. The advantage of this method is that we can argue 
that the effects we measure are causal effects of education. Note however that we are 
possibly identifying the effect of education only for those affected by these laws, i.e. 
those at the lower end of the distribution of education. Because compulsory schooling 
                                                 
15 The average age at diagnosis is around 62 in the full SEER data. Our sample is older but not much more. 
16 See Acemoglu and Angrist (1999), Angrist and Krueger (1991), Lleras-Muney (2002b), Margo and Finnegan, 
(1996) and Schmidt (1996). 
17 The data on compulsory attendance and child labor laws were collected from multiple sources (See Lleras-
Muney, 2002, for details). We use only two laws: the age at which a child had to enter school and the age at 
which he could get a work permit and leave school. The difference between these two variables measures the 
implicit number of years a child had to attend school.   15
laws were most effective in the first half of the 20
th century and they only affected 
whites (see Lleras-Muney 2002a) we restrict our attention to white cohorts born 
between 1901 and 1925.  
As an alternative, we also match individuals with average education levels in 
their cohort, gender, and registry. This measure of education can be calculated from 
the census in 1970, 1980 and 1990. We match individuals to education by decade, i.e. 
individuals diagnosed in the 1970s are matched to the average education in their 
cohort, gender, and registry, calculated from the 1970 census. Unfortunately mean 
education and income are not available for all possible cells. Therefore we must 
further restrict our sample to those individuals for whom average education and 
income is available.   
An advantage of the registry-level average education proxy is that we can also 
calculate total family income for the same cells. We can, therefore, include this 
income control in the regressions.  A problem with this proxy, however, is that it may 
also capture average characteristics of the registry or it may be correlated with 
unobservable characteristics, such as rates of time preference (Fuchs, 1982). Finally 
when using average education, the other coefficients in the regression will most surely 
be biased since the error term now contains the difference between individual and 
mean education, which is most likely correlated with other covariates in our model. 
Throughout the cancer analyses, we provide results using each of these two 
proxies.  Although there are many reasons as we just discussed why the two measures 
might provide different answers, we will feel more confident about our results to the 
extent that both measures provide similar estimates. The two proxies both predict 
income (about equally well), but they are not highly correlated with each other.  The 
simple correlation between them is 0.12.  Using the Census data, we estimate 
individual education levels as a function of registry-cohort level average education 
and compulsory schooling laws.  The result is: 
Education =  0.030 registry mean education + 0.070 compulsory schooling + controls 
           (0.004)                  (0.010) 
where controls include female, age, age
2, cohort, state of birth, registry, census year. 
 
The Effect of Education on Outcomes   16
In the SEER data, we examine the overall effect of education on the probability 
of dying 5 years conditional on being diagnosed with cancer.  We estimate the model 
in (1) above where X includes 47 state of birth, 24 cohort dummies, 8 registry 
dummies, 2 decade dummies, 4 stage of diagnosis dummies, and 80 dummies for 
cancer sites.
18 Since we include state of birth and cohort dummies, the effect of 
compulsory schooling laws is identified from variations in the laws within states over 
time.  
These results are reported in Table 8.  The effect of education on overall 
mortality is negative and significant, using either the compulsory schooling or mean 
education specifications.  The effect of education is greater for cancers affecting men 
than for those affecting women.  This finding is consistent with other studies (e.g., 
Elo and Preston, 1994), which also show that the effect of education on health is 
greater for men than for women.  The effect of education on the probability of dying 
from cancer that we measure here is greater than that suggested by the NHIS all-cause 
data, but notice that in the NHIS we are estimating unconditional probabilities, 
whereas everyone in the SEER data has cancer. 
Using the compulsory schooling laws, we estimate two-stage IV estimates of 
the effect of education in Table 8.  Using the census we can estimate the first stage 
equation of the effect of compulsory schooling on education. Since the model is 
exactly identified and provided that we include the same covariates in both 
estimations, the Two-Sample IV estimate of the effect of education on mortality can 
be calculated as the ratio of the reduced form equation estimate and the first stage 
estimate.
19 We estimate the first stage using the 1960, 1970 and 1980 censuses and 
find that the effect of compulsory schooling on education is 0.079. Using this 
information we calculate that the TSIV estimate of the effect of education on 
mortality is somewhere between –0.02 and –0.05. At the means, this coefficient 
suggests that one more year of schooling reduces the probability of dying post-
diagnosis by 3-7%. The TSIV estimates are close (somewhat larger) to those found by 
Elo and Preston (1996) who report that the effect of one more years of schooling on 5-
year (all cause) mortality is also between 0.02 and 0.05. Since our objective in this 
paper is not to provide accurate estimates of the effect of education on cancer, but 
                                                 
18 Cox proportional hazard models yielded similar results but given that the data are large and that we include 
many variables, these estimations take a very long times to converge. We therefore present linear probability 
models instead.   17
rather to look at whether the education gradient is related to progress, in the 
remainder of the paper we will present reduced form estimates of the effect of 
compulsory schooling on outcomes.
20 
  Next, we look at cancers according to a primary classification of 16 types and 
estimate the effect of education separately for each type of cancer (Table 9).  The 
effect of education on cancer survival differs by type of cancer.  For example, the 
effect of education on survival with urinary system cancers is about 5 times greater 
than the effect on survival with respiratory cancers.  We also find that significant 
gradients by education exist for cancers of the respiratory system, genital system, 
urinary system and for buccal cavity and pharynx cancers.  We do not find statistically 
significant effects for other cancers. The results are similar for the two measures of 
education.    
  We next examine the effects of education on the incidence of cancer (Table 10). 
We calculate annual incidence rates by cancer site, interview year, gender cohort and 
state of birth. In the SEER data we count the number of people diagnosed with cancer 
by interview year, gender, cohort, state of birth and cancer site. Alternatively, we 
calculate rates by cancer site, census year, gender and registry. We then divided by 
the population in that group obtained from the 1970, 1980 and 1990 censuses.  We 
generate estimates of the population for each gender/cohort/state-of-birth/site cell 
using a linear time trend.  We then match these incidence rates with our education 
measures. 
Incidence rates provide a measure of the progress in knowledge about cancer 
risk factors.  However, changes in cancer incidence (both overall, by education level, 
and by cancer subtype) also reflect progress in the incidence and treatment of other 
diseases, particularly cardiovascular disease.  For example, increases in the age-
adjusted incidence of cancer in a group may simply reflect a decline in cardiovascular 
disease mortality for that group. We hypothesize that changes in cancer incidence are 
likely to be associated with behavioral changes – or changes in the incidence of other 
diseases -- rather than changes in medical treatment.  We find that increases in 
compulsory schooling lead to significant reductions in cancer incidence for all cancers 
                                                                                                                                                             
19 This method was used by Dee and Evans (1999).  
20 The inclusion of state-of-birth and cohort specific variables (such as infant mortality, number of hospitals 
per mile and number of doctors per capita in state-of-birth at age 14) did not affect the results. Results 
available upon request.   18
and for several specific types of cancer.  These effects are large (one more year of 
education decreases the incidence rate by about 40%). By contrast, we find that 
increases in mean education at the registry level have little impact on incidence.
21   
The difference between the compulsory schooling and mean education results 
may be an artifact of the aggregation process.  In computing incidence rates, we use 
data that are aggregated.  The aggregation is much greater using mean education 
(N=20,348) than using compulsory schooling laws (N=336,509).  Results using 
compulsory schooling include lots of cells that each contain very few people, while 
results that use mean education have fewer cells but more people in each cell.   
We also find that higher mean education is associated with later age at 
diagnosis, although we do not find this result using the compulsory schooling measure 
(not shown). These coefficients are small: the largest effect of mean schooling 
indicates that a one year increase in mean schooling induces a .1% reduction in the 
age at diagnosis, the implied effect of education is larger – about 1.3% – since mean 
schooling is only partially related to education.   
This result may at first appear surprising since more educated people are likely 
to be diagnosed early.
22  However more educated people are likely to be older, not 
younger, when they get cancer. Given that the more educated are diagnosed at older 
ages, we conclude that the apparent survival advantage of more educated people is not 
simply due to earlier diagnosis.   
  To summarize, our results suggest that education has significant effects on all 
cause morality, on the age of incidence of cancer, stage of cancer diagnosis, and 
survival after cancer diagnosis and (by some measures) on the incidence of cancer.  In 
the SEER data, more educated people are likely to be older when they are diagnosed 
with cancer, they are more likely to survive for 5 years after diagnosis, and they may 
be less likely to get cancer at all. Most of these results are similar regardless of which 
measure of education is used.   
The Effect of Progress on the Gradient in Mortality 
                                                 
21 Higher mean education or compulsory schooling is also correlated with a greater probability that cancer is 
localized when diagnosed.  Localized cancers are likely to be more treatable than cancers found after they have 
spread. Using the coefficient on compulsory schooling, we can calculate that one more year of schooling 
results in an 11% increase in the probability that the cancer is localized at time of diagnosis.  
22 The calculation is not reliable however since, unlike the case of compulsory school, we cannot argue that 
mean education is really an instrument for education.   19
  As we had done for the NHIS, we next relate the education gradients in 
morality by disease with measures of progress for that disease.  In this case, we use 
the three specifications described above (see Tables 11-13).  
  The first panel of Table 11 provides the results of the most constrained 
specification where progress is measured by reductions in age-adjusted mortality.   
Education improves survival in both education proxy specifications, but the results for 
mortality progress are contradictory – the mean education measure suggests that the 
education gradient is steeper where progress has been greater, but the compulsory 
schooling measure shows the opposite.  The 2
nd panel shows the results where 
progress is measured as information about risk factors, proxied by age-adjusted 
incidence.  Here, using either measure of education, we find that progress increases 
the gradient in education.  This implies that the cancer survival gradient in education 
is steepest for those cancers whose incidence is increasing.  This result is consistent 
with our earlier finding in the NHIS that gradients were larger for more prevalent 
diseases. We comment again on this result below.  
  The third panel, which uses our preferred measure of progress, increases in 
survival after diagnosis, shows that the education gradient in survival is steepest for 
those diseases where survival is improving.  The final panel shows results for drugs, 
which also have their effect primarily on survival after diagnosis.  Here too, we find 
that the education gradient is steepest for those diseases where there has been the 
most progress. 
  Table 12 shows results for our preferred flexible specification.  The results in 
this specification for progress measured as incidence, survival, or drugs are similar in 
direction and magnitude to those in the constrained specification, although 
significance levels are somewhat lower. Table 13 shows the results for the fully 
flexible specification.  Again, the results are largely in the same direction as those in 
the more constrained specification but, as we had expected based on the large number 
of dummy variables, the estimates are much smaller in magnitude and are mainly 
statistically insignificant.   
All these results are weighted by the inverse of the variance of the estimated 
education coefficient. Unlike in the NHIS, results weighting by the number of 
individuals with the disease give similar results (See Appendix Table 4). Intuitively, 
this is because in the SEER data the variance of the estimated coefficient of education   20
is estimated using a different sample for each disease: diseases with larger incidence 
have more precisely estimated coefficients. Additionally, note that the probability of 
death is in general larger than 0.5 so that again if we weight by the number of deaths, 
we place more weight on larger diseases. Consequently in the SEER, any weighting 
scheme places relatively more weight on cancers that are more common. 
  We next examine the effect of progress on incidence (Table 14).  Using our 
preferred, flexible specification, we find that again that gradients in incidence become 
larger (more negative) when there is progress in information about risk factors, 
proxied by increasing disease incidence.   
We also find that gradients in incidence become larger (more negative) when 
survival rates improve (or when more drugs are introduced).  If pharmaceutical 
companies targeted their efforts toward diseases that particularly affected more 
educated people, we would expect to see a positive correlation between drugs and the 
gradient.  Instead, we find that highly educated people are less likely to get those 
cancers where we observe the largest improvements in survival.  This result provides 
important evidence suggesting that technological progress drives the gradient, rather 
than the gradient driving technological progress.   
  
VI – Changes in Progress and in the Gradient 
  Our model suggests that progress affects the gradient because more educated 
people are quicker to take advantage of progress.  New technologies later diffuse to 
less educated people.  This theory has implications about the relationship between the 
gradient and the timing of progress.  It suggests that more recent progress should lead 
to widening in the gradient, while progress years earlier should lead to a narrowing of 
the gradient.  The HIV case study is consistent with this pattern.  It also suggests that 
changes in the gradient should be related to changes in progress over time.   
  We have limited data to test these secondary hypotheses.  Because of the 
construction of the SEER education measures, they vary only as cohorts age and there 
is much less variation in predicted education among older cohorts than among younger 
cohorts, confounding efforts to examine changes in the gradient over time. The NHIS 
data cover only a very short time span (1986-1994), but we can conduct preliminary 
analyses of these data.   21
  We estimate two regressions using the NHIS gradients we estimated earlier 
(Table 15).  First, we examine whether more recent or older progress has greater 
effects on the gradient.  We examine how recent progress and older progress affect the 
gradient measured in 1990.  We find that only recent progress leads to a widening in 
the gradient.  Earlier progress appears to have only a very small, negative effect on 
the size of the gradient. Second, we examine whether the change in the education 
gradient by disease is related to the change in progress for that disease.  We find that 
gradients widened most for those diseases where progress was greatest.  These results 
are both consistent with our theory.  
 
VII.  Incidence, gradients and technology: are they related? 
  We conjectured that information about risk factors would be most efficiently 
obtained for diseases with higher prevalence.  Thus, we expect that progress in the 
discovery of disease risk factors is likely to be increasing in disease incidence.   
Similarly, prior research has suggested that technological progress in treatment is 
related to the burden of a disease (Lichtenberg and Waldfogel, 2001).  Thus, another 
way to examine our hypothesis is to see whether factors that predict future rates of 
technological progress also predict future gradients.  An observation that future 
progress and future gradients are both associated with the initial prevalence of a 
disease would provide indirect evidence of our hypothesis.   
  We construct this indirect test by examining the relationship between the 
number of deaths in 1980 (calculated from the Mortality detail files in 1980) and the 
change in age-adjusted mortality for that disease from 1985 to 1995, or alternatively 
from 1990 to 1999 (using CDC data).  We likewise look at the relationship between 
the number of deaths in 1980 by disease and the size of the education gradient for that 
disease in the NHIS from 1986 to 1990. 
  We present the results using un-weighted regressions, and regressions that 
weight by the inverse of the variance of the estimate of the rate of progress EAPC 
(recall that this is a regression of mortality rates on time).
23  Here, the weighted 
regressions place more emphasis on those diseases where the mortality trend is more 
precisely measured. 
                                                 
23 We calculated the variance of the EAPC using the Delta method.   22
  Results of these analyses are reported in Table 16.  The results suggest that the 
higher the number for deaths in a given disease in 1980 the greater the percentage 
decline in age-adjusted mortality from 1985 to 1995. The effect is negative and, when 
weighting by the inverse of the variance, statistically significant. On the other hand, 
the number of deaths appears to be unrelated to progress in the later 1990-1998 
period. Most interestingly, the education gradient 1986-1990 is always larger for 
diseases with more deaths in 1980 (results are significant irrespective of weighing 
scheme). Finally, the number of drugs 1986-1996 is positively correlated with number 
of deaths in 1980 but the coefficient is not significant. 
  Overall these results do suggest that education gradients and progress are 
driven by the same factors, in particular incidence. This suggests that information 
about diseases is increasing in disease incidence.  Innovation in treatment may also be 
occurring more for diseases that are common or are becoming common. 
 
VIII—Mechanisms by Which Education May Affect Outcomes 
Our results are largely (though not uniformly) consistent with our hypothesis, 
suggesting that education may enable people to make more effective use of 
technological progress in reducing mortality or in surviving cancer.  They do not, 
however, explain the mechanisms through which this might occur.   
The existing literature on disparities in cancer treatment between whites and 
blacks and among education groups suggests a broad array of mechanisms that might 
generate the relationship we observe (Shavers and Brown, 2002).  It describes 
differences between groups in receipt of radiation treatment following surgery, 
staging of cancer, nature of radiation therapy received, receipt of adjuvant 
chemotherapy, receipt of surgery, and aggressiveness of treatment.  Groups also differ 
in the rate of referral to oncologists (Earle et al., 2002), the rate at which they 
followed up on screening mammograms (Strzelcyk and Dignan, 2002), and the rate at 
which they participate in clinical trials (Svensson CK, 1989).  There are many ways 
that education could generate these differences.  Education might have direct effects 
(for example, by making it less difficult for people to understand consent procedures 
in clinical trials or to follow new health information) or indirect effects (for example, 
because poorly educated people are less likely to have health insurance or more likely   23
to live in low income areas where oncologists are unavailable and environmental risk 
factors are greater).   
We do not have strong tests that allow us to distinguish between these 
hypotheses, but we consider two here.  First, we compare the effects of education with 
and without controls for average family income.  The results for both the SEER and 
the NHIS are reported in the first 2 columns of Table 17.  We find that average family 
income has an independent effect on cancer survival.  However, we also find that the 
relationship between the education gradient in survival and measures of progress 
persists even when adding controls for family income.  
  Next, we compare the effects of education for those diagnosed before and after 
Medicare eligibility (age 65) in the SEER data.  For the population below Medicare 
eligibility age, education may be related to differences in health insurance and access 
to medical care, but this should be less true of the population 65 and over.  Note that 
because our sample is quite old, the sample of people diagnosed before age 65 is 
relatively small.  Nonetheless, we find effects that go in the same direction for both 
samples and are significant for both sub samples.  Overall, however, the correlations 
between the gradient and progress appear, if anything, greater for the population with 
Medicare than for the population below age 65.   
  Another possible mechanism is that it is not education per se but some other 
characteristic of people who become educated that drives our results.  In this respect, 
we note that the results in the SEER that show the effects of education measured as 
compulsory schooling and as mean education are quite similar in almost every case.  
The compulsory schooling measure can reasonably viewed as showing a causal effect 
of education here, particularly in examining the effects of survival after diagnosis of 
cancer.  These results suggest that education itself, rather than some other 
characteristic of those who choose to become educated, has an effect on cancer 
survival. 
 
IX.  Conclusions and Limitations 
This study finds some evidence to support our hypothesis: gradients appear to 
be larger for diseases where there has been more progress. While we do not find that   24
all measures of progress are correlated with education gradients, the bulk of the 
evidence is quite suggestive.  
Our results do not explain the mechanisms through which gradients arise, 
although our findings suggest that the relationship between the gradient and 
technological progress is not explained away by family income.  Mechanisms are 
likely to vary among diseases and to change over time.  For any specific condition at a 
specific point in time, understanding the mechanisms is critical to reducing the 
gradients.  Over time, however, there is unlikely to be a single mechanism that can 
account for gradients.  
In exploring the relationship between education gradients and rates of 
innovation, we find that gradients are largest for diseases that afflict many, and that 
gradients increase for diseases where incidence is increasing. We also find evidence 
that incidence predicts future innovation. Our interpretation is therefore that 
innovation occurs for diseases that are common or are becoming common and that this 
is a reason why education gradients to appear for those diseases. 
Our data have some important limitations.  In the SEER data, we do not have 
direct measures of education.  Use of proxy measures limits our ability to examine 
changes in gradients over time.  In the NHIS data, our samples are relatively small, 
particularly for some causes of death.  Moreover, the causes of death recorded in the 
NHIS are quite broad, and progress may be very different for some subtypes of disease 
than for others.  Additionally we do not have a unique measure of progress, but rather 
a number of proxies. Our results suggest that progress explains 14% - 31% of 
education gradient, but the precision of this estimate is low given the limited variation 
in education or diseases across our sample. 
  Gradients in health outcomes that arise because of technological progress make the 
distribution of health less equitable.  The existence of a gradient suggests that there exists the 
technological potential for improving the health of the less well off.  But gradients that arise due 
to improvements in the health of the most well off, rather than a diminution in the health of the 
least well off may be a Pareto efficient outcome of technological progress in medicine.     25
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Table 1: Summary Statistics on measures of progress  
 
Variable Obs  Mean  Std.  Dev.  Min  Max 
        
NHIS data        











        
        
SEER cancer data        
Estimated Annual Percent Change in age-
adjusted mortality 
(1)  81 -1.279  2.572 -9.1  8.5 
Estimated Annual Percent Change in the age-
adjusted incidence rate
(2) 80  0.238  2.196  -7.3  9 
Change in the 5-year survival rate, conditional on 
diagnosis
(3)  81  0.079  0.101 -0.36 0.299 
Number of drugs
(4) 81  9.654  10.015  0  48 
        
        
Notes: 
(1) Estimated Annual Percent Change in age-adjusted mortality is calculated as follows: 
EAPC=(e
b-1)*100, 
where b is the coefficient from the following regression: 
log(rate)= constant + b*(calendar year),  
where rate refers to the age-adjusted mortality rate for whites, and the time period used to calculate the change is 1969 to 1999. 
This data are provided by the National Cancer Institute, mortality rates are calculated from Vital Statistics using the entire US. 
Age adjustments use the 2000 US population. This statistics is calculated for men and women jointly with the exception of 
diseases of the genital system which are calculated for each gender separately (site recodes 27010, 27020, 27030, 27040, 27050, 
27060 and 27070 for women; site recodes 28020, 28030 and 28040 for men). 
 (2) Estimated Annual Percent Change in age-adjusted incidence is calculated as follows: 
EAPC=(e
b-1)*100, 
where b is the coefficient from the following regression: 
log(rate)= constant + b*(calendar year),  
where rate refers to the age-adjusted incidence rate for whites, and the time period used to calculate the change is 1973 to 1999. 
This data are provided by the National Cancer Institute, age-adjusted incidence rates are calculated using 9 registries in the SEER 
data base. Age adjustments use the 2000 US population. This statistics is calculated for men and women jointly with the 
exception of diseases of the genital system which are calculated for each gender separately (site recodes 27010, 27020, 27030, 
27040, 27050, 27060 and 27070 for women; site recodes 28020, 28030 and 28040 for men). This statistic is not provided for 
Other Monocytic Leukimia (site recode 35033). 
(3) Change in the 5-year survival rate conditional on diagnosis is calculated as follows: 
(% diagnosed in 1973,1974,1975 who died in 5 years)-(% diagnosed in 1991, 1992, 1993 who died in 5 years), where only whites 
are used to calculate the survival rates. This statistics is calculated by the authors using the SEER mortality data. 
(4) The number of drugs by cancer site is calculated only using the number of distinct active ingredients approved by the FDA. In 
other words, we do not simply calculate the number of drugs in the market, we calculate the number of chemically distinct 
compounds available, which results in a much smaller number of drugs available. Note that it is not always straightforward to 
assign drugs to cancer sites. Therefore there is some measurement error. A list of all cancer drugs, the conditions they are used 
for and their year of approval is available from the authors upon request. 
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SEER cancer data       
Estimated Annual percent change in 




Change in the 5-year survival rate, 
conditional on diagnosis  -0.20  1    
Estimated Annual Percent Change in 
the age-adjusted incidence rate  0.56 -0.05  1  
Number of drugs  0.17  0.30  0.17  1 
      
       
Notes: See previous table for definitions and data sources.   31
TABLE 3: NHIS Summary statistics 
 
 




Dev. Min Max 
       
       
Died in 5 years=1  164373 0.095  0.293  0  1 
Education 164373 12.113  3.239  0  18 
Interview Year (1986=0)  164373 2.222  1.312  0  4 
Hispanic 164373 0.049  0.216  0  1 
Married 164373 0.734  0.442  0  1 
Female 164373 0.540  0.498  0  1 
Age 164373 58.081  12.482  40  90 
Causes of death       
Infectious diseases  164373 0.0014  0.0378  0  1 
Cancer 164373 0.0280  0.1649  0  1 
Diabetes 164373 0.0021  0.0458  0  1 
Cardiovascular Diseases  164373 0.0419  0.2004  0  1 
Respiratory System 
Diseases  164373 0.0077 0.0871  0  1 
Digestive System Diseases  164373 0.0018  0.0427  0  1 
Urinary System  164373 0.0009  0.0300  0  1 
Other Diseases  164373 0.0014  0.0375  0  1 
       
Notes: Data: NHIS-MDC data.  
Sample consists of whites ages 40 and above with no missing values.    32
TABLE 4: Results with the NHIS 
The effect of education on the probability of dying in five years 
(all causes of death) 
 
      
Dependent Variable: dead=1 if 
died within 5 year 
All Males  Females 
      
  
Education -0.0048***  -0.0055*** -0.0035*** 
 (0.0003)  (0.0004)  (0.0004) 
Interview Year (1986=0)  -0.0008  -0.0014  -0.0004 
 (0.0006)  (0.0009)  (0.0007) 
Hispanic -0.0204**  -0.0207** -0.0194** 
 (0.0030)  (0.0048)  (0.0036) 
Married -0.0137***  -0.0354*** -0.0153** 
 (0.0019)  (0.0035)  (0.0022) 
Female -0.0489***    
 (0.0015)    
N   164,710  75,770  88,940 
      
    Notes: Data: NHIS-MDC data. Sample consist of whites ages 40 and above with no 
missing values. Regressions also include single year of age dummies and use person 
weights provided by NHIS.  
   33
TABLE 5: The effect of education by disease type in the NHIS 
 
 
Dependent Variable: dead=1 if died in 5 year  Education
(1) 
 






Cardiovascular Diseases  -0.002355*** 
 (0.000183) 
Respiratory System Diseases  -0.000628*** 
 (0.000083) 
Digestive System Diseases  -0.000068* 
 (0.000034) 
Urinary System  -0.000058** 
 (0.000027) 
Other Diseases  -0.000074** 
 (0.000038) 
  
    Notes: Data: NHIS-MDC data.  
Sample consist of whites ages 40 and above with no missing values.  
Regressions also include single year of age dummies and use person  
weights provided by NHIS.  
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Table 6: Results using the NHIS: Is the Effect of education on mortality larger 
for diseases where more progress has occurred between 1985 and 1995?  
Fully Flexible specification 
 
    
Dependent variable: 
Effect of education on the 
probability of dying within 5 
years of diagnosis (separate 
regression by cause of death) 
Education Education 
WEIGHT  Inverse of variance 
of beta 
Number of deaths by 
disease in 1986 
    
Progress measured by decreases 
in age-adjusted mortality 
  
(-Estimated annual percent   -1.64e-07  -0.0000612*** 
change in age-adjusted mortality)  2.26e-07  (0.0000216) 
    
    
Notes: Standard errors in parentheses. N=55. Each coefficient comes from a separate regression, where the 
effect of education for each cause of death is regressed on a constant and on the relevant measure of innovation, using 
the variance of the effect of education as weights. The effect of education is the coefficient on education in a regression 
of the probability of dying in 5 years after the interview, which includes single age dummies, family income, female 
dummy, Hispanic dummy and interview year. We obtained 55 different coefficients (and their standard errors) by 
running a regression for each cause of death. Sample consists of whites ages 40 and above with no missing data. 
   
* significant at 10%; ** significant at 5%       35
Table 7: SEER Summary Statistics 
 
Variable Obs  Mean  Std.  Dev. Min  Max 
       
Years of compulsory school  711450  6.93  1.05  0  10 
Mean education in cohort, gender and 
registry  711450 10.93  1.06  4.944  16 
Mean total family income in cohort,  
gender and registry  711450 30258.68 36101.75 891.277    527999.5
Female=1 711450  0.46  0.50  0  1 
Birth year  711450  1913.68 6.67  1901  1925 
Age at Diagnosis  711450  69.48  8.00  47  92 
Hispanic=1 711450  0.02  0.14  0  1 
Married=1 711450  0.64  0.48  0  1 
Died within 5 year of diagnosis=1  711450  0.63  0.48  0  1 
Year of diagnosis  711450  1983.65 5.74  1973  1993 
Cancer localized or in situ when diagnosed  711450  0.38  0.48  0  1 
Incidence rate*    0.0028  0.007  0.00006  0.1 
       
Cancer Site (Broad categories)       
Bones and joints  711450  0.00  0.03  0  1 
Brain and other nervous system  711450  0.01  0.11  0  1 
Breast 711450  0.12  0.33  0  1 
Digestive system  711450  0.23  0.42  0  1 
Endocrine system  711450  0.00  0.07  0  1 
Eye and orbit  711450  0.00  0.04  0  1 
Genital system  711450  0.20  0.40  0  1 
Leukimia 711450  0.03  0.16  0  1 
Lymphomas 711450  0.03  0.18  0  1 
Buccal cavity and pharynx  711450  0.03  0.17  0  1 
Multiple Myeloma  711450  0.01  0.11  0  1 
Ill-defined and unspecified sites  711450  0.03  0.17  0  1 
Respiratory system  711450  0.20  0.40  0  1 
Skin 711450  0.02  0.13  0  1 
Soft tissue  711450  0.00  0.06  0  1 
Urinary system  711450  0.07  0.26  0  1 
       
Notes: Total family income was deflated using the CPI. The base year is 1989. 
*incidence rates are calculated using aggregated data (see text)   36
Table 8: The effect of education on the probability of dying in the next 5 years  
conditional on cancer diagnosis (all cancers) 
 
 
          
  Effect of education measured using  
compulsory schooling laws 
Effect of education 
measured using mean 
education in cohort, 
gender and registry 
          
 Effect  of 
compulsory 
school on the 
probability of 








TSIV Effect of 
education on the 
probability of  









          
    













































          
Notes: Standard errors in parentheses. Regressions include age at diagnosis, age at diagnosis squared, 47 state of birth 
dummies, 24 cohort dummies, 80 cancer site dummies, 2 decade dummies, 8 registry dummies and 4 stage of cancer at 
diagnosis dummies. Sample consists of whites born in the 48 states between 1901 and 1925 for whom education could 
be imputed. Standard errors for the TSIV estimates were calculated using the Delta method. 
      
  * significant at 10%; ** significant at 5%; *** significant at 1%     37
Table 9: The effect of education on 5-year death rates  
by cancer type 
 
Dependent Variable:     Died within 5 years of diagnosis 
 N  Compulsory 
schooling 
Mean education 
    
Buccal cavity and pharynx  21356  0.004 -0.010* 
    (0.004) (0.006) 
Digestive system  165944  -0.002 -0.003* 
    (0.001) (0.002) 
Respiratory system  140033  -0.002* -0.001 
    (0.001) (0.002) 
Bones and joints  675  0.022 -0.008 
    (0.023) (0.031) 
Soft tissue  2472  0.002 0.003 
    (0.012) (0.016) 
Skin  12338  0.001 -0.002 
    (0.005) (0.007) 
Breast  87729  -0.002 0.002 
    (0.002) (0.003) 
Genital system  140671  -0.003** -0.010*** 
    (0.001) (0.002) 
Urinary system  52514  -0.010*** -0.006* 
    (0.003) (0.003) 
Eye and orbit  1233  0.009 -0.02 
    (0.018) (0.023) 
Brain and other nervous system 9008  0.001 0.006 
    (0.004) (0.005) 
Endocrine system  3516  -0.002 0.002 
    (0.009) (0.014) 
Lymphomas  24162  -0.001 0.001 
    (0.004) (0.005) 
Multiple Myeloma  9017  0.001 0.004 
    (0.005) (0.007) 
Leukemia  18561  -0.004 -0.002 
    (0.004) (0.005) 
Ill-defined and unspecified sites 22221  0.001 -0.003 
    (0.003) (0.003) 
      
Notes: Each coefficient reported is estimated using a separate regression. Standard errors in parentheses. Regressions 
include age at diagnosis, age at diagnosis squared, diagnosis year, 47 state of birth dummies, 24 cohort dummies, 
cancer site dummies, 2 decade dummies, 8 registry dummies and 4 stage of cancer at diagnosis dummies. Sample 
consists of whites born in the 48 states between 1901 and 1925 for whom education could be imputed. 
    
* significant at 10%; ** significant at 5%; *** significant at 1%     38
Table 10: The Effect of education on Incidence rates 
 





in cohort gender 
and registry
(2) 
Sample    
All cancers  -0.00008*** 0.0000 
 (0.00001)  (0.0000) 
Buccal cavity and pharynx -0.0001  0.0000 
 (0.000)  (0.0001) 
Digestive system  -0.0001***  0.0000 
 (0.000)  (0.0000) 
Respiratory system  -0.0001  -0.0002 
 (0.0001)  (0.0002) 
Bones and joints  0.000  -0.0002* 
 (0.000)  (0.0001) 
Soft tissue  -0.0001**  0.0000 
 (0.0001)  (0.0001) 
Skin -0.0001***  0.0001 
 (0.000)  (0.0001) 
Breast 0.0000  0.0001 
 (0.0001)  (0.0002) 
Genital system  -0.0001  -0.0003 
 (0.0001)  (0.0004) 
Urinary system  -0.0001**  0.0001 
 (0.0000)  (0.0001) 
Eye and orbit  0.0000  0.0000 
 (0.0001)  (0.0000) 
Brain and other nervous 
system  -0.0001 0.0000 
 (0.0000)  (0.0001 
Endocrine system  0.0000  0.0000 
 (0.0000)  (0.0000 
Lymphomas 0.0000  0.0002** 
 (0.0000)  (0.0001) 
Multiple Myeloma  -0.0002**  0.0000 
 (0.0001)  (0.0000) 
Leukimia -0.0001  0.0000 
 (0.0001)  (0.0000) 
Ill-defined and unspecified 
sites  -0.0001** 0.0000 
 (0.0001)  (0.0001) 
    
Notes: standard errors in parenthesis. 
(1)Data that has been aggregated by cancer site, diagnosis year, gender, cohort and state-of-birth. N=336,509. 
Regressions include age, age squared, diagnosis year, state-of-birth dummies, cohort dummies, cancer site 
dummies and census year dummies. 
(2) Data that has been aggregated by cancer site, diagnosis year, gender, cohort and registry of residence. 
N=20,348. Regressions include age, age squared, diagnosis year, registry dummies, cohort dummies, cancer 
site dummies and census year dummies.   39
Table 11: Is the Effect of Education on mortality larger for diseases where 
more progress has occurred between 1973 and 1998? 
  
    
Dependent variable: 









    
Progress measured by decreases in age-
adjusted mortality 
  
Education   -0.002***  -0.005*** 
 (0.001)  (0.001) 
Education*(-Estimated annual percent 





    
    
Progress measured by increases in age-
adjusted incidence rates    
Education 0.001**  0.000 
 (0.001)  (0.001) 
Education*(Estimated annual percent 





    
Progress measured by increases in 5 year-
survival rates after diagnosis 
  
Education -0.001  0.010*** 
 (0.001)  (0.001) 
Education*change in 5-year survival rate 





    
Progress measured by the number of drugs available 













    
    
Notes: Standard errors in parentheses. Regressions include diagnosis year, age at diagnosis, age at diagnosis 
squared, 47 state of birth dummies, 24 cohort dummies, 80 cancer site dummies, 2 decade dummies, 8 
registry dummies and 4 stage of cancer at diagnosis dummies. Sample consists of whites born in the 48 states 
between 1901 and 1925 for whom education could be imputed. 
    
* significant at 10%; ** significant at 5%; *** significant at 1%         40
Table 12: Is the Effect of education on mortality larger for diseases where 
more progress has occurred between 1973 and 1998?  
Flexible specification-Including interaction between site and stage 
 
Dependent variable: 
Effect of education on the probability of dying 






    
Progress measured by decreases in age-adjusted 
mortality 
  
(-Estimated annual percent change in age-  0.00069  -0.00125 
adjusted mortality)  (0.00051)  (0.00088) 
    
Progress measured by increases in incidence rates    
(Estimated annual percent change in age   -0.00119** 0.00026 
adjusted incidence rates)  (0.00055)  (0.00099) 
    
Progress measured by increases in the 5 year-
survival rates after diagnosis 
  
change in 5-year survival rate conditional on 
diagnosis 
-0.02706** -0.0596***
 (0.01257)  (0.0218) 
  
Progress measured by the number of drugs available for treatment 
(Match by 3 digit icd9 code)  
number of drugs  -0.00015  -0.00039**
 (0.00010)  (0.00017) 
    
    
Notes: Standard errors in parentheses. N=81. Each coefficient comes from a separate regression, where the effect of 
education for each cancer is regressed on a constant and on the relevant measure of innovation, using the variance of 
the effect of education as weights. The effect of education is the coefficient on education in a regression of the 
probability of dying, which includes age at diagnosis, age at diagnosis squared, 47 state of birth dummies, 24 cohort 
dummies, 2 decade dummies, 8 registry dummies, 80 cancer site dummies and 4 stage of cancer at diagnosis dummies. 
We obtained 78 different coefficients (and their standard errors) by running a regression where education is interacted 
with a dummy fir each cancer site. Sample consists of whites born in the 48 states between 1901 and 1925 for whom 
education could be imputed.   
   
* significant at 10%; ** significant at 5%    
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Table 13: Is the Effect of Education on mortality larger for diseases where 
more progress has occurred between 1973 and 1998?  
Fully flexible specification 
 
Dependent variable: 
Effect of education on the probability of dying 






    
Progress measured by decreases in age-adjusted 
mortality 
  
(-Estimated annual percent change in age-  -0.00003  -0.00073 
adjusted mortality)  (0.00001)  (0.00056) 
    
Progress measured by increases in incidence rates    
(Estimated annual percent change in age   0.00002  -0.00017 
adjusted incidence rates)  (0.00001)  (0.00050) 
    
Progress measured by increases in the 5 year-
survival rates after diagnosis 
  
change in 5-year survival rate conditional on 
diagnosis  -0.0007 
 
-0.01780** 
 (0.0077)  (0.00818) 
    
Progress measured by the number of drugs available for treatment 
(Match by 3 digit icd9 code)  
number of drugs  0.00001  -0.00001 
 (0.00005)  (0.00006) 
    
    
Notes: Standard errors in parentheses. N=78. Each coefficient comes from a separate regression, where the effect of 
education for each cancer is regressed on a constant and on the relevant measure of innovation, using the variance of 
the effect of education as weights. The effect of education is the coefficient on education in a regression of the 
probability of dying, which includes age at diagnosis, age at diagnosis squared, 47 state of birth dummies, 24 cohort 
dummies, 2 decade dummies, 8 registry dummies and 4 stage of cancer at diagnosis dummies. We obtained 78 different 
coefficients (and their standard errors) by running a regression for each cancer site. There are 3 cancers for which the 
regressions could not be estimated because of small sample sizes. Sample consists of whites born in the 48 states 
between 1901 and 1925 for whom education could be imputed.       
 
* significant at 10%; ** significant at 5%; *** significant at 1%         42
Table 14: Is the Effect of Education on incidence larger for diseases where 




Effect of education on the annual incidence rate 





      
Progress measured by decreases in age-adjusted 
mortality 
    
Estimated annual percent change in age-    0.00001  -0.00000 
adjusted mortality    (0.00001)  (0.00001) 
      
Progress measured by increases in incidence rates      
Estimated annual percent change in age     -0.00003***  -0.00002* 
adjusted incidence rates    (0.00001)  (0.00001) 
      
Progress measured by increases in the 5 year-
survival rates after diagnosis 
    






   (0.00015)  (0.00019) 
    
Progress measured by the number of drugs available for 
treatment (Match by 3 digit icd9 code)   
 
number of drugs    -0.00002***  -0.00000 
   (0.00000)  (0.00000) 
      
      
Notes: Standard errors in parentheses. N=81. Each coefficient comes from a separate regression, where the effect of education for 
each cancer is regressed on a constant and on the relevant measure of innovation, using the variance of the effect of education as 
weights. The effect of education is the coefficient on education in a regression of the probability of dying, which includes age at 
diagnosis, age at diagnosis squared, 47 state of birth dummies, 24 cohort dummies, 2 decade dummies, 8 registry dummies, 80 
cancer site dummies and 4 stage of cancer at diagnosis dummies. We obtained 78 different coefficients (and their standard errors) 
by running a regression where education is interacted with a dummy fir each cancer site. Sample consists of whites born in the 48 
states between 1901 and 1925 for whom education could be imputed.      
 
* significant at 10%; ** significant at 5%       43
Table 15:  Changes in the 4-Year Mortality Education Gradient over Time 
(NHIS) 
 
  Change in the Effect of 
Education on the Probability 
of Dying 1990 vs. 1986 
Effect of Education on the 
Probability of Dying 1990 
   
Change in the Rate of 
Technological Progress  
  
1990-1993 vs. 1983-1986  -0.000019**   
 (0.000007)  
Tech Progress 1983-1985    -0.000015 
   (0.000014) 
Tech Progress 1986-1989    0.000006 
   (0.000022) 
Tech Progress 1990-1993    -0.000055** 
   (0.000027) 
   
Notes: Standard errors in parentheses. N=55. Each coefficient comes from a separate regression, where the effect of 
education for each cause of death is regressed on a constant and on the relevant measure of innovation, using the 
variance of the effect of education as weights. The effect of education is the coefficient on education in a regression of 
the probability of dying in 5 years after the interview, which includes single age dummies, family income, female 
dummy, Hispanic dummy and interview year. We obtained 55 different coefficients (and their standard errors) by 
running a regression for each cause of death. Sample consists of whites ages 40 and above with no missing data. 
   
* significant at 10%; ** significant at 5%   
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Table 16: Does incidence predict progress and gradients? 
 















































--   Variance of 
EAPC 
1985-1995 
-- Variance  of 
EAPC 
 




         
Number of 
deaths in 1980 
-1.93e-06     -5.83e-06**   9.52e-07     -4.15e-07     -2.41e-09**    -1.70e-09**   4.37e-06    
  (9.32e-06)  (1.53e-06)  (9.40e-06)      (3.37e-07) (2.24e-10) (2.76e-10)  (0.0000252) 
         
         
Notes: Standard errors in parentheses.  Each coefficient comes from a separate regression, where the effect of education for each cause of death is regressed on a constant 
and on the relevant measure of innovation, using the variance of the effect of education as weights. The effect of education is the coefficient on education in a regression 
of the probability of dying in 5 years after the interview, which includes single age dummies, family income, female dummy, Hispanic dummy and interview year. We 
obtained 55 different coefficients (and their standard errors) by running a regression for each cause of death. Sample consists of whites ages 40 and above with no 
missing  data.     
* significant at 10%; ** significant at 5%       45
 
Table 17: Is the education-mortality gradient only due to access? 
 
Dependent variable: 
Effect of education on the probability 
of dying within 5 years of diagnosis 

















        
NHIS data        
Progress measured by decreases in 
age-adjusted mortality 
      
(-Estimated annual percent change in          
age-adjusted mortality)  -0.0000612*** -0.0000402**    
 (0.0000216)  (0.0000192)     
number of drugs approved 1973-1993  4.64e-06  5.44e-06    
 (4.93e-06)  (4.18e-06)     
SEER cancer data        
Progress measured by decreases in 
age-adjusted mortality 
      
(-Estimated annual percent change in   -0.00076  -0.00079  0.00062  -0.00110 
age- adjusted mortality)  (0.00129) (0.00128)  (0.00116)  (0.00095) 
        
Progress measured by decreases in 
incidence rates        
(-Estimated annual percent change in   0.00429***  0.00422***  0.00490***  0.00103 
age adjusted incidence rates)  (0.00109)  (0.00109)  (0.00089)  (0.00099) 
        
Progress measured by increases in the 
5 year-survival rates after diagnosis 
      
change in 5-year survival rate 









        
Progress measured by the number of drugs available for treatment (Match 
by 3 digit icd9 code)   
number of drugs  -0.00040***  -0.00039***  -0.00053***  -0.00011 
 (0.00014)  (0.00014)  (0.00011)  (0.00011) 
        
Notes: Standard errors in parentheses. N=81. Each coefficient comes from a separate regression, where the effect of education for each 
cancer is regressed on a constant and on the relevant measure of innovation, using the variance of the effect of education as weights. 
The effect of education is the coefficient on education in a regression of the probability of dying, which includes age at diagnosis, age 
at diagnosis squared, 47 state of birth dummies, 24 cohort dummies, 2 decade dummies, 8 registry dummies, 80 cancer site dummies 
and 4 stage of cancer at diagnosis dummies. We obtained 78 different coefficients (and their standard errors) by running a regression 
where education is interacted with a dummy fir each cancer site. Sample consists of whites born in the 48 states between 1901 and 
1925 for whom education could be imputed.    
  
* significant at 10%; ** significant at 5%       46
Figure 1: HIV/AIDS Case study 

























FDA approves AZT FDA approves first protease inhibitor
 
 
Source: 1984-1992 from the AIDS Microfiche Data on CDC Wonder. We divided the number of 
deaths per year by the cumulative population (number diagnosed total minus the death from 
previous years). 1993-2001 is from the CDC HIV/AIDS Surveillance Report Vol. 13(2). We 
divided the death rate by the total number of people living with HIV/AIDS.   47
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Appendix A: Progress measures for 81 cancer sites 
 
Code  Cancer Site Name 
# of white 
persons born 































20010  Lip  2976 -5.5 0.036 -3.2  12  7 
20020 Tongue  4166  -1.7  0.164  0.5  12  7 
20030 Salivary  gland  1467  -1.5  -0.009  0.6  12  7 
20040 Floor  of  mouth  2579  -4.5  0.034  -2  12  7 
20050  Gum  &  other  mouth  3631 -1.4 0.055 -0.4  12  7 
20060  Nasopharynx  699  -1.5 0.225 -0.9  12  7 
20070 Tonsil  2031  -2.6  0.208  0.2  12  7 
20080 Oropharynx  646  1.3  0.109  -0.3  12  7 
20090 Hypopharynx  2345  -2.5  0.090  -1  12  7 
20100  Other buccal cavity and pharynx  816  -0.9  0.091  -0.1  12  7 
21010  Esophagus  7415 1.2 0.079 1.2  0  0 
21020 Stomach  14866  -2.7  0.046  -2  1  1 
21030  Small  intestine  1998 0.2 0.130 2.5  0  0 
21041 Cecum  16445  -0.9  0.098  0.1  8  3 
21042 Appendix  394  -0.9  -0.235  1.3  8  3 
21043 Ascending  colon  9755  -0.9  0.123  0.5  8  3 
21044 Hepatic  flexure  3197  -0.9  0.111  2.1  8  3 
21045  Transverse  colon  7421 -0.9 0.140 -1.3  8  3 
21046 Splenic  flexure  2825  -0.9  0.118  0.1  8  3 
21047 Descending  colon  5650  -0.9  0.147  -2  8  3 
21048  Sigmoid  colon  26684 -0.9 0.137 -1.1  8  3 
21049  Large intestine, NOS  3418  -0.9  -0.001  -0.6  8  3 
21051  Rectosigmoid  junction  10896 -2.9 0.143 -1.1  8  3 
21052  Rectum  20641 -2.9 0.145 -0.9  8  3 
21060  Anus, anal canal & anorectum  1597  4.3  0.044  2.1  0  0 
21071  Liver  3995  0.8 -0.038 2.4  0  0 
21072  Intrahepatic bile duct  602  8.5  -0.078  9  0  0 
21080 Gallbladder  2687  -3  0.025  -2.5  0  0 
21090  Other  biliary  2569 -2.2 0.054 -0.7  6  4 
21100  Pancreas  21280 -0.1 -0.013 -0.4  12  8 
21110  Retroperitoneum  618  -4.4 0.201 -0.6  0  0 
21120  Peritoneum, omentum & mesentery  404  0.4  0.172  6.7  0  0 
21130  Other digestive organs  587  -2.8  0.022  -0.2  0  0 
22010 
Nasal cavity, middle ear & accessory 
sinuses  1134 -2.6 0.060 -0.2  0  0 
22020 Larynx  9818  -0.7  0.009  -1  4  1 
22030  Lung and bronchus  127003  1.6  0.031  1  23  10 
22050 Pleura  1718  0  -0.029  2.4  0  0 
22060 
Trachea, mediastinum & other respiratory 
organs  360  -4.5 0.073 -1.3  0  0 
23000  Bones & joints  675  -3.2  0.173  0.6  11  6 
24000  Soft tissue (including heart)  2472  1.8  0.071  0.9  20  5   50
Appendix A (continued): Progress measures for 81 cancer sites 
 
Code   Cancer Site Name 
# of white 
persons born 































25010  Melanomas-skin  11289 1.4 0.134 3.6  22  8 
25020  Other non-epithelial skin  1049  -0.3  -0.356  4.9  1  1 
26000 Breast  87729  -0.4  0.140  1.3  48  10 
27010 Cervix  7630  -2.9  0.059  -2  12  5 
27020  Corpus  26216 -0.4 -0.055 -1.2  1  0 
27030 Uterus,  NOS  361  -2.3  -0.087  -2  8  3 
27040 Ovary  13758  -0.4  0.154  0.5  25  7 
27050  Vagina  834  -1.4 0.099 -1.2  0  0 
27060 Vulva  2281  -0.8  0.096  0.9  1  1 
27070  Other female genital organs  621  -0.5 0.173 -0.2  0  0 
28010  Prostate  87592 0.5 0.298 3.2  34  10 
28020  Testis  358  -4.7  0.201  2 14 7 
28030  Penis  826  -1.9 0.106 -1.4  2  1 
28040  Other male genital organs 194  -3  0.023  0.8  0  0 
29010 Bladder  35240  -1  0.098  0.5  16  4 
29020  Kidney and Renal pelvis  14873  0.7  0.102  1.8  15  4 
29030 Ureter  1626  -0.3  0.090  -1  0  0 
29040  Other urinary organs  775  -1.2  0.128  -0.6  0  0 
30000  Eye & orbut  1233  -2.6  0.046  -0.6  1  0 
31010  Brain  8712 1.5 0.092 0.8  8  3 
31040  Other nervous system  296  -9.1  0.169  0.7  8  3 
32010 Thyroid  2979  -1.3  0.036  2  7  2 
32020  Other endocrine ( include. Thymus)  537  0  0.160  1.3  13  6 
33011  Hodgkin's  Disease-Nodal  1899 -4.6 0.168 -0.2  27  6 
33012 Extranodal  52  -4.6  0.160  1.4  2  0 
33041  Non- Hodgkin's Lymphomas--Nodal  17122  1.9  0.078  1.9  38  9 
33042  Extranodal  5089 1.9 0.054 4.7  40  9 
34000  Multiple  myeloma  9017 1.3 0.100 0.7  20  3 
35011  Acute lymphocytic leukimia  490  -1.6  0.248  1.2  22  2 
35012 Chronic  lymphocytic  7328  0.6  0.083  -0.5  20  2 
35013  Other  lymphocytic  267  -5.8 0.070 -1.8  14  1 
35021  Acute  granulocytic  4509 0.2 0.077 0.5  15  4 
35022  Chronic  granulocytic  2507 -0.7 0.166 -0.2  15  2 
35023  Other  granulocytic  536  -4.5 0.159 -7.3  4  1 
35031  Acute monocytic Leukimia  339  -5.3  0.127  0.5  3  0 
35032 Chronic  monocytic  leukimia  38  -2.9  -0.118  -4  1  0 
35033 Other  monocytic  leukimia  50  -8.9  0.119    1  0 
35041 Other  acute  leukimia  1080  0.5  -0.058  -0.2  3  1 
35042 Other  chronic  65  -0.6  -0.141  -2  2  0 
35043  Aleukemic, subacute, and NOS  1352  1.2  0.162  0.5  12  2 
37000  Ill defined and unspecified sites  22221  0.8  0.050  -0.7  22  9   51
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20  Shigellosis and amebiases  1  15.04  2 
40  Tuberculosis of respiratory system  6  -4.70  0 
50 Other  tuberculosis  1  0.00  1 
80 Meningococcal  infection  1  0.00  0 
90 Septicemia  105  -1.27  6 
120 Viral  Hepatitis  9  12.94  0 
140  All other infections  75  -2.30  60 
160  Neoplasms-lip, oral cavity and pharynx  43  -1.67  0 
170 Neoplasms-digestive  system  870  -0.74  2 
180 Neoplasm-respiratory  system  1151  0.74  0 
190 Neoplasms-breast  304  -0.95  0 
200 Neoplasms-genital  organs  408  0.47  1 
210 Neoplasms-urinary  organs  145  0.39  0 
220 Neoplasms-unspecified  site  478  -0.26  6 
230 Leukemia  130  0.17  5 
240  Other malignant neoplasms of lymphatic tissues  210  1.68  10 
250 Begin  neoplasms  39  0.25  33 
260 Diabetes  274  3.43  1 
270 Nutritional  deficiencies  16  -0.13  1 
280 Anemias  18  -0.27  0 
290 Meningitis  1  -7.31  6 
320  Rheumatic fever and rheumatic heart disease  38  -3.85  0 
330  Hypertensive heart disease  111  0.36  0 
340  Hypertensive heart and renal disease  9  -2.70  0 
360 Acute  myocardial  infarction  1670  -3.71  2 
370  Other forms of ischemic heart disease  31  -4.40  0 
380 Angina  pectoris  12  -4.70  10 
390  Old myocardial infection, chronic heart disease  1465  -2.03  4 
400  Other diseases of endocardium  98  3.65  1 
410  All other forms of heart disease  1035  -2.02  26 
420  Hypertension with or without renal disease  47  2.94  24 
440  Intracerebral and other intracranial hemorrhage  135  -0.90  0 
450 Cerebral  Thrombosis  79  -8.25  1 
460 Cerebral  embolism  2  -2.75  1 
470  All other late effects of cerebrovascular disease  537  -0.82  2 
480 Atheosclerosis  76  -6.10  0 
490  Other disease of arteries, arterioles and capillaries  165  0.10  3 
500  Acute bronchitis and bronchiolitis 5  -4.56  1 
520 Pneumonia  348  -0.38  29 
530 Influenza  8  -7.48  2 
550  Bronchitis, chronic and unspecified 18  -2.17  14 
         52
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560 Emphysema  131  0.68  3 
570 Asthma  26  1.99  5 
580  other chronic obstructive pulmonary diseases  492  2.56  2 
590  Ulcer of stomach and duodenum  38  -3.34  15 
600  Apendicitis  2 -8.44 0 
610 Hernia  38  -0.77  0 
620  Chronic liver disease and cirrhosis  155  -1.61  2 
630  Cholelithiasis and other disorders of the gallbladder  19  -3.18  1 
650  Acute glomerulonephritis and nephrotic  syndrome  2 0.00 0 
660  Chronic glomerulonephritis and nephrotic syndrome  13  -0.99  0 
670 Renal  failure  99  -1.03  0 
680  Infections of the kidney  5  -9.06  1 
690  Hyperplasia of prostate  1  0.00  4 
730 Congenital  anomalies  14  -1.22  2 
       
   53
Appendix Table 1:  
Case Studies of HIV/AIDS Treatment Disparities Over Time 
 
Study Treatment  Outcome 
Characteristic Percent  with 
cumulative 








Black 47 78 
White 20 59 
Hispanic 34 73 
Exposure Group 
IVDU 32 65 
Homosexual 45 78 
Education: 
Some HS 22  65 
HS Diploma 35  70 







College degree 49  79 











White - - - 
Black .43 .58 .81 
Hispanic .54 .56 .75 
Exposure Group 









Non-IVDU - - - 
    





White .46 .79 
Black - - 
Exposure Group 
IVDU .84 1.09 




Non-IVDU  -   54
Appendix Table 2: The effect of education on age at diagnosis 
by cancer type 
 
Dependent Variable:     Age at diagnosis 
 N  Compulsory 
schooling 
Mean education 
        
All cancer sites  711450  -0.003 0.027*** 
    (0.004) (0.005) 




    (0.023) (0.030) 
Digestive system  165944  -0.002 0.017* 
    (0.008) (0.010) 
Respiratory system  140033  -0.011 0.015 
    (0.01) (0.012) 
Bones and joints  675  -0.015 -0.008 
    (0.125) (0.165) 
Soft tissue  2472  0.011 0.111 
    (0.061) (0.083) 
Skin  12338  0.033 -0.018 
    (0.029) (0.035) 
Breast  87729  -0.001 0.064*** 
    (0.012) (0.018) 
Genital system  140671  0.000 0.033*** 
    (0.008) (0.010) 
Urinary system  52514  -0.001 0.005 
    (0.015) (0.018) 
Eye and orbit  1233  -0.099 0.038 
    (0.091) (0.116) 




    (0.037) (0.049) 
Endocrine system  3516  -0.036 -0.167** 
    (0.054) (0.083) 
Lymphomas  24162  -0.002 -0.019 
    (0.018) (0.024) 
Multiple Myeloma  9017  0.010 -0.029 
    (0.033) (0.045) 
Leukimia  18561  -0.013 0.021 
    (0.023) (0.030) 
Ill-defined and   22221        -0.013  0.072*** 
unspecified sites    (0.020) (0.028) 
        
Notes: Each coefficient reported is estimated using a separate regression. Standard errors in parentheses. 
Regressions include diagnosis year, age, age squared, 47 state of birth dummies, 24 cohort dummies, cancer 
site dummies, 2 decade dummies, 8 registry dummies and 4 stage of cancer at diagnosis dummies. Sample 
consists of whites born in the 48 states between 1901 and 1925 for whom education could be imputed. 
    
* significant at 10%; ** significant at 5%; *** significant at 1%     55
Appendix Table 3: The effect of education on probability that cancer is 
in situ or localized at time of diagnosis- by cancer type 
 
Dependent Variable:     Cancer stage in situ or localized 
 N  Compulsory  schooling  Mean  education 
    
All cancer sites  711450  0.000 0.001 
    (0.001) (0.001) 




    (0.004) (0.006) 
Digestive system  165944  -0.001 0.003 
    (0.001) (0.002) 
Respiratory system  140033  -0.002 0.000 
    (0.002) (0.002) 
Bones and joints  675  0.029 -0.013 
    (0.025) (0.033) 
Soft tissue  2472  -0.012 -0.008 
    (0.013) (0.018) 
Skin  12338  0.007 -0.004 
    (0.005) (0.006) 
Breast  87729  0.004 0.006 
    (0.002) (0.004) 
Genital system  140671  0.003* -0.003 
    (0.002) (0.002) 
Urinary system  52514  0.002 0.007** 
    (0.003) (0.003) 
Eye and orbit  1233  -0.023 0.003 
    (0.016) (0.021) 




    (0.001) (0.002) 
Endocrine system  3516  -0.018* -0.012 
    (0.011) (0.017) 
Lymphomas  24162  -0.001 0.000 
    (0.003) (0.004) 
Multiple Myeloma  9017  - - 
      
Leukimia  18561  - - 





      
      
Notes: Each coefficient reported is estimated using a separate regression. Standard errors in parentheses. 
Regressions include 47 state of birth dummies, 24 cohort dummies, cancer site dummies, 2 decade dummies, 
8 registry dummies. Sample consists of whites born in the 48 states between 1901 and 1925 for whom 
education could be imputed.   
  
* significant at 10%; ** significant at 5%; *** significant at 1%     56
Appendix Table 4: Weighting SEER regression by number of 
individuals with the disease (alternative specification to Table 12) 
 
Dependent variable: 
Effect of education on the probability of dying within 





    
Progress measured by decreases in age-adjusted 
mortality 
  
(-Estimated annual percent change in age-  0.00022 -0.00175 
adjusted mortality)  (0.00048) (0.00121) 
    
Progress measured by increases in incidence rates    
(Estimated annual percent change in age   -0.00094** -0.00323*** 
adjusted incidence rates)  (0.00045) (0.00112) 
    
Progress measured by increases in the 5 year-survival 
rates after diagnosis 
  
change in 5-year survival rate conditional on diagnosis -0.01426* -0.09576*** 
  (0.00758) (0.01629) 
  
Progress measured by the number of drugs available for treatment 
(Match by 3 digit icd9 code)  
number of drugs  -0.00003 -0.00022* 
  (0.00005) (0.00012) 
    
    
Notes: Standard errors in parentheses. N=81. Each coefficient comes from a separate regression, where the 
effect of education for each cancer is regressed on a constant and on the relevant measure of innovation, 
using the variance of the effect of education as weights. The effect of education is the coefficient on 
education in a regression of the probability of dying, which includes age at diagnosis, age at diagnosis 
squared, 47 state of birth dummies, 24 cohort dummies, 2 decade dummies, 8 registry dummies, 80 cancer 
site dummies and 4 stage of cancer at diagnosis dummies. We obtained 78 different coefficients (and their 
standard errors) by running a regression where education is interacted with a dummy for each cancer site. 
Sample consists of whites born in the 48 states between 1901 and 1925 for whom education could be 
imputed.     
* significant at 10%; ** significant at 5%    
 